A Dye for the Detection of Cancer of the Tongue and Mouth

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test if an investigational dye, called PARPi-FL, can be used to detect this type of cancer. This will be the first time that PARPi-FL is being tried in people. First, the investigators will test the safety of PARPi-FL at different doses to find out what effects, if any, it has on people. The investigators will also see which amount of PARPi-FL is best suited to detect cancers of the mouth and tongue.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Memorial Sloan Kettering Cancer Center
• Treatments: Olaparib

Criteria

Inclusion Criteria:

• Patient is ≥ 18 years old

• Histologically or cytologically proven squamous cell carcinoma of the oral cavity or pharynx (OSCC)

• Scheduled to undergo surgery at MSK

• Any tumor stage, any N, M0

• ECOG performance status 0 or 1

Exclusion Criteria:

• Any surgical therapy in the area of the oral cavity or pharynx within the last 2 weeks

• Prior or ongoing treatment with a PARP1 inhibitor

• Known hypersensitivity to Olaparib

• Known hypersensitivity to PEG300 Eligibility criteria will be assessed by an experienced oral surgeon, typically the Co-PI of the study.